Stay updated on Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Sign up to get notified when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.

Latest updates to the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page
- CheckyesterdayChange DetectedAdded detailed definitions for response criteria (iRECIST/RECIST) and endpoints (CR, PR, SD, PD) under Outcome Measures. Included an external resource reference (Genetic and Rare Diseases Information Center) related to head and neck cancer terminology.SummaryDifference0.8%

- Check9 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-visible changes to the Study Details page are indicated.SummaryDifference0.1%

- Check16 days agoChange DetectedUpdated the IMPORTANCE trial entry with slow recruitment and termination status, along with a 'Results Posted' update. Added detailed study plan information and key dates.SummaryDifference3%

- Check23 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page shows a minor version update from v3.4.1 to v3.4.2; no study content or functionality changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision banner updated from v3.4.0 to v3.4.1; no impact on study information or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.